LIFECORE BIOMEDICAL, INC. Increase (Decrease) in Other Operating Liabilities
LIFECORE BIOMEDICAL, INC. (LFCR) reported Increase (Decrease) in Other Operating Liabilities of $64.00 thousand for the 6-month period ending 2024-11-24, per its 10-Q filed 2025-01-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2025-01-02
- LIFECORE BIOMEDICAL, INC. increase (decrease) in other operating liabilities for the quarter ending 2024-11-24 was -$1.09M.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in other operating liabilities for the quarter ending 2024-08-25 was $1.15M.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in other operating liabilities for the quarter ending 2023-11-26 was -$246.00K.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in other operating liabilities for the quarter ending 2023-08-27 was -$2.53M.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month |
|---|---|---|
| 2024-11-24 | -$1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-01-02 | $64.00K 10-Q · filed 2025-01-02 |
| 2024-08-25 | $1.15M 10-Q · filed 2024-10-04 | |
| 2023-11-26 | -$246.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-01-02 | -$2.78M 10-Q · filed 2025-01-02 |
| 2023-08-27 | -$2.53M 10-Q · filed 2024-10-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |